Capital World Investors Boosts Amgen Stake by 11.5%

Institutional investor now owns nearly 3.5% of the biotech company's shares

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Capital World Investors, a major institutional investor, increased its stake in Amgen Inc. (NASDAQ:AMGN) by 11.5% during the third quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 18,795,474 shares of the medical research company's stock, representing a 3.49% ownership position valued at over $5.3 billion.

Why it matters

Amgen is one of the world's largest biotechnology companies, developing innovative medicines to treat serious illnesses. The increased investment by Capital World Investors, a respected institutional fund, signals continued confidence in Amgen's long-term growth potential despite broader market volatility.

The details

In its latest 13F filing, Capital World Investors reported acquiring an additional 1,935,876 shares of Amgen during the third quarter. This raised the firm's total stake in the company to 18,795,474 shares, or 3.49% of Amgen's outstanding stock. Capital World Investors is now Amgen's 29th largest shareholder.

  • Capital World Investors filed its 13F report for the third quarter of 2025 on March 10, 2026.

The players

Capital World Investors

A major institutional investment firm that manages over $2 trillion in assets globally.

Amgen Inc.

A leading global biotechnology company that discovers, develops, manufactures and delivers human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Capital World Investors in Amgen underscores the biotech firm's strong fundamentals and growth prospects, even as the broader market faces uncertainty. This vote of confidence from a major institutional investor could signal further upside for Amgen's stock price in the months ahead.